Navigation Links
Genetic defect found to cause severe epilepsy and mental retardation
Date:10/12/2010

BEER-SHEVA, Israel, October 12, 2010 A research team at Ben-Gurion University of the Negev and Soroka University Medical Center in Beer-Sheva, Israel has detected a genetic mutation resulting in a progressive disease of severe mental retardation and epilepsy beginning at infancy. The research was just published in the American Journal of Human Genetics.

The team, led by BGU Prof. Ohad Birk of the National Institute for Biotechnology in the Negev determined that the defect is associated with the production of the 21st amino acid, selenocysteine (SEC), which leads to progressive brain atrophy.

According to Prof. Birk, "One out of every 40 Jews of both Moroccan and Iraqi ancestry may be carriers of this mutation. As the disease is both severe and common, testing for these mutations is expected to become a routine prenatal genetic screening test in these two populations, enabling prevention of future cases."

It is believed that further research will identify other mutations in the same gene as the cause of mental retardation with epilepsy in other communities. As the disease is progressive, elucidation of its molecular mechanisms might open new venues to treatment, preventing disease progression.

The human genetic code, as deciphered some 50 years ago, encodes 20 amino acids which are the building blocks of all proteins in the human body. However, in recent years it became apparent that a 21st amino acid exists: selenium, entering the body in food, is incorporated in the human tissues into what is known as selenocysteine.

This 21st amino acid is unique in that it is encoded by what is normally a stop codon that is, a DNA sequence that normally instructs the protein building system to end the chain of amino acids, terminating the generated protein. In contrast with most genes, some 25 genes have a unique component that manipulates the stop codon so that instead of terminating the evolving protein chain, it
'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
2. Studies provide new insights into the genetics of obesity and fat distribution
3. Study reveals cancer-linked epigenetic effects of smoking
4. Twins provide clue that genetic epilepsy can originate in the embryo
5. Researchers find first genetic evidence for loss of teeth in the common ancestor of baleen whales
6. Notre Dame and Wyoming scientists genetically engineer silkworms to produce artificial spider silk
7. Insecticides from genetically modified corn present in adjacent streams
8. Light workout: Stanford scientists use optogenetics to effectively stimulate muscle movement in mice
9. Genetic ancestry: A new look at racial disparities in head and neck cancer
10. Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team
11. Hard-wired for chocolate and hybrid cars? How genetics affect consumer choice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... technologies from more than 850 scientific, technical and educational ... Annual Meeting, Frontiers in Optics (FiO) 2011, being held Oct. ... Claire hotels in San Jose, Calif. Held in conjunction with ... Society (APS) Division of Laser Science (DLS), the meeting will ...
... The U.S. Department of Energy (DOE) awarded $5.5 ... develop the oilseed plant camelina ( Camelina sativa ) ... totaling $156 million, were awarded by the Advanced Research ... cutting-edge energy technology projects aimed at dramatically improving how ...
... 2011 A young scientist who led research into the use ... disease has been named the winner of the Young Investigator Award ... be presented with her award at The Stem Cell Symposium, hosted ... The $10,000 prize is awarded annually to a young scientist whose ...
Cached Biology News:Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 2Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 3Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 4Danforth Plant Science Center awarded major bioenergy grant from US Department of Energy 2Danforth Plant Science Center awarded major bioenergy grant from US Department of Energy 3Regenerating eyes using cells from hair: Stem Cells awards research into stem cell deficiency 2
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Placement -, - $10 Million Principal Amount of Debt Exchanged for ... ... Stock -, DALLAS, Nov. 8 Access Pharmaceuticals, Inc.,(OTC Bulletin ... million recapitalization. The Company has entered,into agreements with institutional investors to ...
... Clinical ... ... Genta,Incorporated (Nasdaq: GNTA ) today announced the presentation of ... in combination with Abraxane(R) (paclitaxel protein-bound,particles for injectable suspension) (albumin-bound; ...
... p.m. (Pacific); ... , SAN DIEGO, Nov. 7 ADVENTRX Pharmaceuticals,Inc. ... company,focused on commercializing proprietary product candidates for the treatment,of ... three-month and nine-month periods ended September 30, 2007. ...
Cached Biology Technology:Access Pharmaceuticals Announces $19.5 Million Recapitalization 2Access Pharmaceuticals Announces $19.5 Million Recapitalization 3Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 2Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 3Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
... plastic feeding tubes for rodent oral gavage ... risk of perforation and trauma. Plus they ... cleaning and the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
Biology Products: